Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation CADTH. Long-acting beta-agonists and inhaled corticosteroids for treatment of chronic obstructive pulmonary disease: a review of the clinical efficacy and cost-effectiveness. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). Rapid Response - Summary with Critical Appraisal. 2013 Authors' conclusions Compared with tiotropium monotherapy, adding formoterol to tiotropium statistically significantly improved the lung function (FEV1) in the treatment of patients with moderate to severe COPD; Adding budesonide/formoterol to tiotropium statistically significantly improved lung function (FEV1) and reduced the frequency of severe exacerbation, and appears cost effective compared with tiotropium monotherapy in the treatment of severe COPD. The long term comparative clinical effectiveness, harms and the cost effectiveness of these COPD treatment strategies remain to be established. Indexing Status Subject indexing assigned by CRD MeSH Adrenergic beta-Agonists; Bronchodilator Agents; Corticosterone; Humans; Pulmonary Disease, Chronic Obstructive Language Published English Country of organisation Canada English summary An English language summary is available. Address for correspondence Canadian Agency for Drugs and Technologies in Health (CADTH), 865 Carling Avenue, Suite 600, Ottawa, Ontario Canada, K1S 5S8 Email: requests@cadth.ca AccessionNumber 32014000163 Date abstract record published 28/01/2014 |